A new trading day began on Friday, with BridgeBio Pharma Inc (NASDAQ: BBIO) stock price down -0.58% from the previous day of trading, before settling in for the closing price of $45.12. BBIO’s price has ranged from $21.72 to $45.18 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -3.04% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -3.92%. With a float of $160.76 million, this company’s outstanding shares have now reached $189.83 million.
In an organization with 730 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 96.95%, operating margin of -547.57%, and the pretax margin is -528.55%.
BridgeBio Pharma Inc (BBIO) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of BridgeBio Pharma Inc is 15.39%, while institutional ownership is 85.61%. The most recent insider transaction that took place on Jun 24 ’25, was worth 4,422,800. In this transaction Director of this company sold 100,000 shares at a rate of $44.23, taking the stock ownership to the 879,979 shares. Before that another transaction happened on Jun 26 ’25, when Company’s client’s wife is a BoD proposed sale 1,891 for $44.03, making the entire transaction worth $83,261.
BridgeBio Pharma Inc (BBIO) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.6 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3.92% per share during the next fiscal year.
BridgeBio Pharma Inc (NASDAQ: BBIO) Trading Performance Indicators
Here are BridgeBio Pharma Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 66.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.53, a number that is poised to hit -0.74 in the next quarter and is forecasted to reach -1.58 in one year’s time.
Technical Analysis of BridgeBio Pharma Inc (BBIO)
Let’s dig in a bit further. During the last 5-days, its volume was 4.13 million. That was better than the volume of 3.08 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 92.13%.
During the past 100 days, BridgeBio Pharma Inc’s (BBIO) raw stochastic average was set at 96.38%, which indicates a significant increase from 91.02% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 34.77% in the past 14 days, which was lower than the 50.33% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $36.99, while its 200-day Moving Average is $31.41. However, in the short run, BridgeBio Pharma Inc’s stock first resistance to watch stands at $45.49. Second resistance stands at $46.13. The third major resistance level sits at $46.77. If the price goes on to break the first support level at $44.21, it is likely to go to the next support level at $43.57. Assuming the price breaks the second support level, the third support level stands at $42.93.
BridgeBio Pharma Inc (NASDAQ: BBIO) Key Stats
With a market capitalization of 8.52 billion, the company has a total of 189,881K Shares Outstanding. Currently, annual sales are 221,900 K while annual income is -535,760 K. The company’s previous quarter sales were 116,630 K while its latest quarter income was -167,420 K.
